Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $64.5 million as the latest value for Q1 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) changed 0.1% to $64.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $64.5 million, a 0.1% change, with the full-year FY2023 number at $63.3 million, up 20.58% from a year prior.
  • Shares Outstanding (Weighted Average) was $64.5 million for Q1 2025 at Crescent Biopharma, roughly flat from $64.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $64.5 million in Q1 2025 to a low of $50.7 million in Q1 2021.
  • A 5-year average of $57.6 million and a median of $56.4 million in 2022 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 20.58% in 2023, then rose 0.1% in 2025.
  • Crescent Biopharma's Shares Outstanding (Weighted Average) stood at $51.5 million in 2021, then rose by 2.1% to $52.5 million in 2022, then grew by 20.58% to $63.3 million in 2023, then increased by 1.8% to $64.5 million in 2024, then rose by 0.06% to $64.5 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Shares Outstanding (Weighted Average) are $64.5 million (Q1 2025), $64.5 million (Q3 2024), and $64.5 million (Q2 2024).